RESEARCH ARTICLE

Hypoxia-induced activity loss of a photo-responsive microtubule inhibitor azobenzene combretastatin A4

  • Yang An 1 ,
  • Chao Chen 1 ,
  • Jundong Zhu 1 ,
  • Pankaj Dwivedi 2 ,
  • Yanjun Zhao , 1 ,
  • Zheng Wang , 1
Expand
  • 1. School of Pharmaceutical Science & Technology, Tianjin Key Laboratory for Modern Drug Delivery & High Efficiency, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin University, Tianjin 300072, China
  • 2. School of Engineering Science, University of Science and Technology of China, Hefei 230027, China

Received date: 20 Apr 2019

Accepted date: 15 May 2019

Published date: 15 Oct 2020

Copyright

2019 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature

Abstract

The conformation-dependent activity of azobenzene combretastatin A4 (Azo-CA4) provides a unique approach to reduce the side-effects of chemotherapy, due to the light-triggered conformation transition of its azobenzene moiety. Under hypoxic tumor microenvironment, however, the high expression of azoreductase can reduce azobenzene to aniline. It was postulated that the Azo-CA4 might be degraded under hypoxia, resulting in the decrease of its anti-tumor activity. The aim of this study was to verify such hypothesis in HeLa cells in vitro. The quantitative drug concentration analysis shows the ratiometric formation of degradation end-products, confirming the bioreduction of Azo-CA4. The tubulin staining study indicates that Azo-CA4 loses the potency of switching off microtubule dynamics under hypoxia. Furthermore, the cell cycle analysis shows that the ability of Azo-CA4 to induce mitotic arrest is lost at low oxygen content. Therefore, the cytotoxicity of Azo-CA4 is compromised under hypoxia. In contrast, combretastatin A4 as a positive control maintains the potency to inhibit tubulin polymerization and break down the nuclei irrespective of light irradiation and oxygen level. This work highlights the influence of hypoxic tumor microenvironment on the anti-tumor potency of Azo-CA4, which should be considered during the early stage of designing translational Azo-CA4 delivery systems.

Cite this article

Yang An , Chao Chen , Jundong Zhu , Pankaj Dwivedi , Yanjun Zhao , Zheng Wang . Hypoxia-induced activity loss of a photo-responsive microtubule inhibitor azobenzene combretastatin A4[J]. Frontiers of Chemical Science and Engineering, 2020 , 14(5) : 880 -888 . DOI: 10.1007/s11705-019-1864-6

Acknowledgements

The work was financially supported by the National Natural Science Foundation of China (Grant No. 21650110447).
1
Mollman J E. Cisplatin neurotoxicity. New England Journal of Medicine, 1990, 322(2): 126–127

DOI

2
Singal P K, Iliskovic N. Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 1998, 339(13): 900–905

DOI

3
Bae Y H, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release, 2011, 153(3): 198–205

DOI

4
Lu D, Tao R, Wang Z. Carbon-based materials for photodynamic therapy: A mini-review. Frontiers of Chemical Science and Engineering, 2019, 13(2): 310–323

DOI

5
Kwon I K, Lee S C, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release, 2012, 164(2): 108–114

DOI

6
Wilhelm S, Tavares A J, Dai Q, Ohta S, Audet J, Dvorak H F, Chan W C W. Analysis of nanoparticle delivery to tumours. Nature Reviews. Materials, 2016, 1(5): 1–12

DOI

7
Hu Q, Bomba H N, Gu Z. Engineering platelet-mimicking drug delivery vehicles. Frontiers of Chemical Science and Engineering, 2017, 11(4): 624–632

DOI

8
Xin K, Li M, Lu D, Meng X, Deng J, Kong D, Ding D, Wang Z, Zhao Y. Bioinspired coordination micelles integrating high stability, triggered cargo release, and magnetic resonance imaging. ACS Applied Materials & Interfaces, 2017, 9(1): 80–91

DOI

9
Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Advanced Drug Delivery Reviews, 2016, 98: 19–34

DOI

10
Webster R M. Combination therapies in oncology. Nature Reviews. Drug Discovery, 2016, 15(2): 81–82

DOI

11
Doroshow J H, Simon R M. On the design of combination cancer therapy. Cell, 2017, 171(7): 1476–1478

DOI

12
Li H, Li M, Chen C, Fan A, Kong D, Wang Z, Zhao Y. On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier. International Journal of Pharmaceutics, 2015, 495(1): 572–578

DOI

13
Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Advanced Drug Delivery Reviews, 2015, 91: 3–6

DOI

14
Peer D, Karp J M, Hong S, Farokhzad O C, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2(12): 751–760

DOI

15
Zhang P, Ye J, Liu E, Sun J, Zhang S J, Lee J, Gong J, He H, Yang V C. Aptamer-coded DNA nanoparticles for targeted doxorubicin delivery using pH-sensitive spacer. Frontiers of Chemical Science and Engineering, 2017, 11(4): 529–536

DOI

16
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 2013, 12(11): 991–1003

DOI

17
Torchilin V P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews. Drug Discovery, 2014, 13(11): 813–827

DOI

18
Li X, Gao M, Xin K, Zhang L, Ding D, Kong D, Wang Z, Shi Y, Kiessling F, Lammers T, Cheng J, Zhao Y. Singlet oxygen-responsive micelles for enhanced photodynamic therapy. Journal of Controlled Release, 2017, 260: 12–21

DOI

19
Tao R, Gao M, Liu F, Guo X, Fan A, Ding D, Kong D, Wang Z, Zhao Y. Alleviating the liver toxicity of chemotherapy via pH-responsive hepatoprotective prodrug micelles. ACS Applied Materials & Interfaces, 2018, 10(26): 21836–21846

DOI

20
Gao J, Li J, Geng W C, Chen F Y, Duan X, Zheng Z, Ding D, Guo D S. Biomarker displacement activation: A general host-guest strategy for targeted phototheranostics in vivo. Journal of the American Chemical Society, 2018, 140(14): 4945–4953

DOI

21
He H, Sun L, Ye J, Liu E, Chen S, Liang Q, Shin M C, Yang V C. Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents. Journal of Controlled Release, 2016, 240: 67–76

DOI

22
Chen C, Zhao J, Gao M, Meng X, Fan A, Wang Z, Zhao Y. Photo-triggered micelles: Simultaneous activation and release of microtubule inhibitors for on-demand chemotherapy. Biomaterials Science, 2018, 6(3): 511–518

DOI

23
Liu Y, Liu Y, Bu W, Cheng C, Zuo C, Xiao Q, Sun Y, Ni D, Zhang C, Liu J, Shi J. Hypoxia induced by upconversion-based photodynamic therapy: Towards highly effective synergistic bioreductive therapy in tumors. Angewandte Chemie International Edition, 2015, 54(28): 8105–8109

DOI

24
Borowiak M, Nahaboo W, Reynders M, Nekolla K, Jalinot P, Hasserodt J, Rehberg M, Delattre M, Zahler S, Vollmar A, Trauner D, Thorn-Seshold O. Photoswitchable inhibitors of microtubule dynamics optically control mitosis and cell death. Cell, 2015, 162(2): 403–411

DOI

25
Engdahl A J, Torres E A, Lock S E, Engdahl T B, Mertz P S, Streu C N. Synthesis, characterization, and bioactivity of the photoisomerizable tubulin polymerization inhibitor azo-combretastatin A4. Organic Letters, 2015, 17(18): 4546–4549

DOI

26
Sheldon J E, Dcona M M, Lyons C E, Hackett J C, Hartman M C. Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog. Organic & Biomolecular Chemistry, 2016, 14(1): 40–49

DOI

27
Rastogi S K, Zhao Z, Barrett S L, Shelton S D, Zafferani M, Anderson H E, Blumenthal M O, Jones L R, Wang L, Li X, Streu C N, Du L, Brittain W J. Photoresponsive azo-combretastatin A-4 analogues. European Journal of Medicinal Chemistry, 2018, 143: 1–7

DOI

28
Muroyama A, Lechler T. Microtubule organization, dynamics and functions in differentiated cells. Development, 2017, 144(17): 3012–3021

DOI

29
Castle B T, Odde D J. Optical control of microtubule dynamics in time and space. Cell, 2015, 162(2): 243–245

DOI

30
Perche F, Biswas S, Wang T, Zhu L, Torchilin V P. Hypoxia-targeted siRNA delivery. Angewandte Chemie International Edition, 2014, 53(13): 3362–3366

DOI

31
Li J, Meng X, Deng J, Lu D, Zhang X, Chen Y, Zhu J, Fan A, Ding D, Kong D, Wang Z, Zhao Y. Multifunctional micelles dually responsive to hypoxia and singlet oxygen: Enhanced photodynamic therapy via interactively triggered photosensitizer delivery. ACS Applied Materials & Interfaces, 2018, 10(20): 17117–17128

DOI

32
Hanahan D, Weinberg R A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5): 646–674

DOI

33
Rankin E B, Giaccia A J. Hypoxic control of metastasis. Science, 2016, 352(6282): 175–180

DOI

34
Tang J, Huang C, Shu J, Zheng J, Ma D, Li J, Yang R. Azoreductase and target simultaneously activated fluorescent monitoring for cytochrome c release under hypoxia. Analytical Chemistry, 2018, 90(9): 5865–5872

DOI

35
Wang L, Huang X, Wang B, Zhao J, Guo X, Wang Z, Zhao Y. Mechanistic insight into the singlet oxygen-triggered expansion of hypoxia-responsive polymeric micelles. Biomaterials Science, 2018, 6(7): 1712–1716

DOI

36
Li M, Gao M, Fu Y, Chen C, Meng X, Fan A, Kong D, Wang Z, Zhao Y. Acetal-linked polymeric prodrug micelles for enhanced curcumin delivery. Colloids and Surfaces. B, Biointerfaces, 2016, 140: 11–18

DOI

37
Beharry A A, Woolley G A. Azobenzene photoswitches for biomolecules. Chemical Society Reviews, 2011, 40(8): 4422–4437

DOI

38
Piao W, Hanaoka K, Fujisawa T, Takeuchi S, Komatsu T, Ueno T, Terai T, Tahara T, Nagano T, Urano Y. Development of an azo-based photosensitizer activated under mild hypoxia for photodynamic therapy. Journal of the American Chemical Society, 2017, 139(39): 13713–13719

DOI

39
Verwilst P, Han J, Lee J, Mun S, Kang H G, Kim J S. Reconsidering azobenzene as a component of small-molecule hypoxia-mediated cancer drugs: A theranostic case study. Biomaterials, 2017, 115: 104–114

DOI

40
Dong M, Babalhavaeji A, Samanta S, Beharry A A, Woolley G A. Red-shifting azobenzene photoswitches for in vivo use. Accounts of Chemical Research, 2015, 48(10): 2662–2670

DOI

41
Wu S, Butt H J. Near-infrared-sensitive materials based on upconverting nanoparticles. Advanced Materials, 2016, 28(6): 1208–1226

DOI

42
Bandara H M, Friss T R, Enriquez M M, Isley W, Incarvito C, Frank H A, Gascon J, Burdette S C. Proof for the concerted inversion mechanism in the trans-cis isomerization of azobenzene using hydrogen bonding to induce isomer locking. Journal of Organic Chemistry, 2010, 75(14): 4817–4827

DOI

43
Aliprandi A, Mauro M, De Cola L. Controlling and imaging biomimetic self-assembly. Nature Chemistry, 2016, 8(1): 10–15

DOI

44
Meng L, Cheng Y, Gan S, Zhang Z, Tong X, Xu L, Jiang X, Zhu Y, Wu J, Yuan A, Hu Y. Facile deposition of manganese dioxide to albumin-bound paclitaxel nanoparticles for modulation of hypoxic tumor microenvironment to improve chemoradiation therapy. Molecular Pharmaceutics, 2018, 15(2): 447–457

DOI

45
Sheng Y, Nesbitt H, Callan B, Taylor M A, Love M, McHale A P, Callan J F. Oxygen generating nanoparticles for improved photodynamic therapy of hypoxic tumours. Journal of Controlled Release, 2017, 264: 333–340

DOI

46
Cheng Y, Cheng H, Jiang C, Qiu X, Wang K, Huan W, Yuan A, Wu J, Hu Y. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nature Communications, 2015, 6(1): 8785

DOI

47
Kolemen S, Ozdemir T, Lee D, Kim G M, Karatas T, Yoon J, Akkaya E U. Remote-controlled release of singlet oxygen by the plasmonic heating of endoperoxide-modified gold nanorods: Towards a paradigm change in photodynamic therapy. Angewandte Chemie International Edition, 2016, 55(11): 3606–3610

DOI

Outlines

/